Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age22-39
SponsorPeking Union Medical College Hospital

About this trial

This study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen ("Xiehe DOR Bushen Tongzhi Formula" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulation induction therapy with ovulation monitoring and timed intercourse) in improving the natural cumulative clinical pregnancy rate in infertile patients with kidney deficiency-type diminished ovarian reserve (DOR).

Eligibility criteria

Qualifiers

Female patients aged 22 to 39 years (inclusive).

Meet the diagnostic criteria for diminished ovarian reserve (requiring at least two of the following: Basal FSH 10-25 IU/L; AMH < 1.1 ng/mL; AFC < 7) and infertility(defined as the failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse).

Meet the diagnostic criteria for kidney deficiency syndrome in traditional Chinese medicine

Voluntarily participate in this study and provide written informed consent.

Disqualifiers

Patients with premature ovarian insufficiency or premature ovarian failure (basal FSH >25 IU/L), organic pathologies such as ovarian tumors, endometrial tuberculosis, intrauterine adhesions, or endometrial injuries, as well as those with congenital adrenal hyperplasia or Cushing's syndrome;

Infertility caused by organic lesions of the fallopian tubes, uterus, cervix, etc.

Infertility due to male factors (based on semen analysis reports, meeting the diagnostic criteria for oligoasthenoteratozoospermia according to the WHO 5th edition standards).

DOR caused by iatrogenic factors (such as pelvic surgery, radiotherapy/chemotherapy, uterine artery embolization, etc.).

Trial design

Treatments tested in this trial

  • Western Medicine
  • Traditional Chinese Medicine
  • Placebo

Treatment groups

320 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Peking Union Medical College Hospital

Lead sponsor

Dongfang Hospital Beijing University of Chinese Medicine

Collaborator

Beijing University of Chinese Medicine

Collaborator

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborator

Hunan University of Traditional Chinese Medicine

Collaborator

Shandong University

Collaborator

Xiamen University

Collaborator

Beijing Obstetrics and Gynecology Hospital

Collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Collaborator

The Third Affiliated Hospital of Beijing University of Chinese Medicine

Collaborator

Hunan Provincial Maternal and Child Health Care Hospital

Collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine

Collaborator

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Collaborator

Institute of Basic Medical Sciences CAMS

Collaborator

First Affiliated Hospital of Heilongjiang Chinese Medicine University

Collaborator

Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan)

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator

Shenyang Women's and Children's Hospital

Collaborator